9512 Results for "

targeted modification

" in MedChemExpress (MCE) Product Catalog:
Products (9512)

9512 Results for "targeted modification" in MCE Product Catalog:

5
5 Cited Publications
Cat. No.: HY-128892
CAS No.: 1808714-73-9
Purity:  99.42%
Target:  

Autophagy

Research Areas:  

Neurological Disease

EN6 is a small-molecule in vivo autophagy activator that covalently targets cysteine 277 in the ATP6V1A subunit of the lysosomal v-ATPase. EN6-mediated modification of ATP6V1A uncouples v-ATPase from Rag, leading to inhibition of mTORC1 signalling, increased lysosomal acidification, and activation of autophagy. EN6 also scavenges TDP-43 aggregates (causative agents of frontotemporal dementia) in a lysosome-dependent manner .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-W441014
Target:  

Liposome

Research Areas:  

Others

DSPE-PEG2000-NHS is a PEG-modified phospholipid derivative that can be used to prepare liposomes. DSPE-PEG2000-NHS is commonly employed as a linker molecule for the surface modification of liposomes to confer targeting capabilities. DSPE-PEG2000-NHS can be used in the study of drug delivery .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-155489
CAS No.: 3029515-97-4
Purity:  98.55%
Research Areas:  

Cancer

DDO-2728 (compound 19) is a selective AlkB homologue 5 (ALKBH5) inhibitor with an IC50 of 2.97 μM. DDO-2728 increases the abundance of N 6 methyladenosine (m 6A) modifications, inducing cell apoptosis and cycle arrest. DDO-2728 suppresses tumor growth in the MV4 11 xenograft model with favorable safety profile, shows the potential of targeting ALKBH5 in cancer research .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-RI00449A
Target:  

MicroRNA

Research Areas:  

Cancer

hsa-miR-21-5p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P1291
CAS No.: 201422-03-9
PKI 14-22 amide, myristoylated is a selective, cAMP-dependent, competitive PKA inhibitor with Ki=~36 nM. The myristoylation modification of PKI 14-22 amide, myristoylated makes it more permeable to cell membranes and blood-brain barriers than the precursor molecule. PKI 14-22 amide, myristoylated can block the phosphorylation of cAMP-dependent downstream targets (such as CREB). PKI 14-22 amide, myristoylated can prevent the development of morphine analgesic tolerance in mice, and also inhibits protein translation and negative-strand RNA synthesis of Zika virus. PKI 14-22 amide, myristoylated can be used in research fields such as opioid tolerance mechanisms and antiviral drugs .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P1291A
PKI 14-22 amide, myristoylated TFA is a selective, cAMP-dependent, competitive PKA inhibitor with Ki=~36 nM. The myristoylation modification of PKI 14-22 amide, myristoylated TFA makes it more permeable to cell membranes and blood-brain barriers than the precursor molecule. PKI 14-22 amide, myristoylated TFA can block the phosphorylation of cAMP-dependent downstream targets (such as CREB). PKI 14-22 amide, myristoylated TFA can prevent the development of analgesic tolerance in mice, and also inhibits protein translation and negative-strand RNA synthesis of Zika virus. PKI 14-22 amide, myristoylated TFA can be used in research fields such as opioid tolerance mechanisms and antiviral drugs .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-13943
CAS No.: 1202759-32-7
Purity:  99.92%
Target:  

Btk

Research Areas:  

Cancer

CNX-774 is an orally active, irreversible and selective BTK inhibitor, with an IC50 of < 1 nM. CNX-774 specifically targets Cysteine 481 of Btk for covalent modification .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-153084A
Target:  

mRNA CD19

Research Areas:  

Cancer

CD19 CAR mRNA (Human) expresses CAR protein that specifically targets human CD19. CD19 CAR mRNA can trigger transitory expression of CAR, allowing T cells to be targeted without permanent genetic modification. CD19 CAR mRNA targets CD19 which is a transmembrane glycoprotein primarily expressed on B lymphocytes and is important in B cell activation. CD19 CAR mRNA can be studied in cancer research such as lymphoma and leukemia .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-113138
CAS No.: 2140-69-4
Purity:  99.05%
Synonyms: N3-Methyluridine
3-Methyluridine (m 3U; N3-Methyluridine) is a methylated nucleotide present in ribosomal RNA (rRNA), mainly targeting specific base sites of RNA molecules such as 23S rRNA. 3-Methyluridine can introduce a methyl group at the N3 position of uracil, affecting the secondary structure stability and base pairing ability of RNA, and regulating ribosome function. For example, it affects ribosomal subunit binding and tRNA interaction. 3-Methyluridine is often used as a key raw material for the synthesis of modified nucleotides, and is used to construct RNA oligonucleotides containing methylation modifications to study the effects of RNA methylation on gene expression and drug resistance .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99014
CAS No.: 1864871-20-4
Synonyms: ARGX-110

Research Areas:  

Inflammation/Immunology Cancer

Cusatuzumab (ARGX-110) is a selective competitive blocker targeting CD70 (with an equilibrium dissociation constant of 17 pM for binding to human CD70). Cusatuzumab also possesses enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. It is a humanized IgG1 monoclonal antibody, artificially synthesized through humanization and genetic engineering modifications (CH2 region mutation to enhance effector function). Cusatuzumab has a dual mechanism of action: firstly, it competitively blocks the interaction between CD70 and CD27, inhibiting the CD27-NF-κB signaling pathway, reducing regulatory T cell (Treg) activation and tumor cell proliferation; secondly, by enhancing binding to FcγRIIIa, it mediates ADCC and antibody-dependent cellular phagocytosis (ADCP), directly lysing CD70-positive tumor cells. Cusatuzumab can efficiently eliminate leukemia stem cells (LSCs), induce tumor cell differentiation and apoptosis, restore immune surveillance, and target CD70-positive tumors. Cusatuzumab is used in the study of acute myeloid leukemia (AML) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-148775B
Purity:  ≥95.0%
PLGA-PEG-MAL (20KDA-5.0KDA, LA:GA RATIO 40:60) is a biodegradable amphipathic polymeric nanocarrier of poly (lactic-co-glycolic acid)-block-poly (ethylene glycol) (PLGA-PEG-Mal) that allows covalent modification of functional molecules. PLGA-PEG-MAL (20KDA-5.0KDA, LA:GA RATIO 40:60) modified with Angiopep-2 can cross the blood-brain barrier and exhibits targeting selectivity for glioblastoma cells. PLGA-PEG-MAL (20KDA-5.0KDA, LA:GA RATIO 40:60) can capture tumor-derived protein antigens, and exerts immunomodulatory effects when conjugated with anti-OX40 antibody; when used in combination with A2-CL/Dbait nanoparticles and radiotherapy, it prolongs survival time and reduces tumor volume in glioblastoma mouse models. PLGA-PEG-MAL (20KDA-5.0KDA, LA:GA RATIO 40:60) can be used for studies related to bacterial wound infections and glioblastoma .
loading...
    loading...
Cat. No.: HY-W440911
Research Areas:  

Cancer

DSPE-PEG2000-Cy5 is a Cy5 (HY-D0821) fluorophore-labeled conjugate of distearoylphosphatidylethanolamine and polyethylene glycol, as well as a liposome component. The Cy5 fluorophore is commonly used for labeling proteins and nucleic acids in imaging, flow cytometry and genomic applications. DSPE-PEG2000-Cy5 supports cell membrane modification, in vivo tumor targeting research and long-term in vivo circulation of its liposomal formulations (Ex/Em=633/670 nm) .
loading...
    loading...
Cat. No.: HY-128522
CAS No.: 2436544-27-1
Purity:  99.59%
Target:  

Ras

Research Areas:  

Cancer

ARS-1323-alkyne is a covalent inhibitor probe that covalently binds to the Switch-II pocket (S-IIP) of the KRAS G12C mutant protein. ARS-1323-alkyne visualizes the covalent modification of KRAS G12C and quantitatively measures the binding efficiency of the inhibitor to the target. ARS-1323-alkyne can be used to validate the target occupancy of KRAS G12C inhibitors and the synergistic mechanism of combination therapy .
loading...
    loading...
Cat. No.: HY-119390
CAS No.: 1869921-96-9
Target:  

DNA Methyltransferase

Research Areas:  

Cancer

AA-CW236 is a MGMT (O6-methylguanine DNA methyltransferase) inhibitor. AA-CW236 targets MGMT active site Cys145 for covalent modification .
loading...
    loading...
Inactive ASO (in vivo) sodium
0 Images
CCTATAGGACTATCCAGGAA
Cat. No.: HY-153734
Purity:  92.18%
Inactive ASO (in vivo) sodium is an inactive Antisense Oligonucleotide. ASO is a class of oligonucleotide molecules, usually composed of 20-30 bases, used to interfere with or regulate gene expression. Inactive ASO (in vivo) sodium is not targeted in the rodent genome and can be used as a negative control for Tofersen. Inactive ASO (in vivo) sodium contains thiophosphate skeleton modification and MOE modification. Cytosine in Inactive ASO (in vivo) is 5' methylcytosine. See References for the location of chemical modifications
loading...
    loading...
Cat. No.: HY-172351B
CAS No.: 24991-53-5
PEG10000-bis-amine is a bisamine-terminated polyethylene glycol that serves as a key starting material for the preparation of cholesterol-conjugated polyethylene glycol derivatives. After radioiodination modification, PEG10000-bis-amine significantly prolongs plasma retention time and exhibits enhanced tumor accumulation in a subcutaneous melanoma mouse model. PEG10000-bis-amine has important application value in studies of tumor-targeted delivery and drug modification .
loading...
    loading...
Cat. No.: HY-RI00057
Target:  

MicroRNA

Research Areas:  

Cancer

hsa-miR-107 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
loading...
    loading...
Cat. No.: HY-150655
CAS No.: 2252283-32-0
Target:  

HSP

Research Areas:  

Cancer

Hsp90-IN-15 is an Hsp90 inhibitor with anticancer activity. Hsp90-IN-15 induces cell apoptosis, arrests the cell cycle at S phase and decreases the expression level of Hsp90 in Hela cell .
loading...
    loading...
Cat. No.: HY-133848
CAS No.: 83130-01-2
Synonyms: OK-135
Target:  

Insecticide

Research Areas:  

Infection

Alanycarb (OK-135) is a broad-spectrum oxime carbamate insecticide with contact and oral toxicity. Alanycarb is effective against a wide variety of insect pests and is a pro-insecticide. The principal active molecule produced by the biological modification of Alanycarb within target organisms is methomyl .
loading...
    loading...
Cat. No.: HY-144187
CAS No.: 2755304-16-4
Research Areas:  

Cancer

PRMT5-IN-16 (Compound 20) is a PRMT5 inhibitor with anti-tumor activity. PRMT5 is a type of protein arginine methyltransferase, and is a new anti-tumor target related to epigenetic modification .
loading...
    loading...